In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Introduction: Cancer is considered as one of the deadliest human diseases today. Angiogenesis, the propagation of new blood vessels from pre-existing vasculature, is a critical step in the progression of cancer as it is essential in the growth and metastasis of tumors. Hence, suppression of angiogenesis is a promising approach in cancer therapy. Syringin, a phenylpropanoid glycoside with a molecular formula of \( \text{C}_{17}\text{H}_{22}\text{O}_{9} \), has been found to exhibit chemopreventive effects. However, its anti-angiogenic activity and the underlying mechanism of action are still unknown.

Methods: In this work, in ovo chorioallantoic membrane (CAM) assay has been conducted to evaluate the effect of syringin on neovascularization. Additionally, reverse molecular docking studies have been performed in order to identify the probable enzyme targets in the angiogenesis pathway.

Results: Treatment with syringin showed significant dose-dependent inhibition of blood vessel length and junctions in the CAM of duck eggs; the anti-angiogenic activity of syringin at 100 \( \mu \)M and 200 \( \mu \)M is comparable with 200 \( \mu \)M of the positive control celecoxib. The results of reverse docking studies indicate that syringin binds the strongest to dihydrofolate reductase (DHFR) and, to some extent, with transforming growth factor-beta receptor type 1 (TGF-βR1), vascular endothelial growth factor receptor 2 (VEGFR2), and matrix metalloproteinase-2 (MMP-2). Furthermore, ADME models revealed that syringin potentially possesses excellent pharmacokinetic and toxicity profiles.

Conclusion: This study demonstrates the potential of syringin as an anti-angiogenic agent and elicits further investigations to establish its application in cancer suppression.

Keywords: syringin, angiogenesis, cancer, molecular docking, reverse docking, dihydrofolate reductase, DHFR, TGF-βR1, VEGFR2, MMP-2

Introduction
Cancer ranks as the second leading cause of death worldwide, accounting to 9.6 million mortalities in 2018.\(^1\) It is a complex disorder characterized by the abnormal proliferation and spread of malignant cells into surrounding tissues.\(^2\) Progression of this condition relies on its capacity to promote angiogenesis,\(^3\) which is the intricate process of initiating new blood vessels from pre-existing ones.\(^4\) The new capillary vessels are fundamental as they supply oxygen and sustenance that are indispensable in the growth and survival of malignancy.\(^5\) Moreover, these vessels are essential in the spread of cancer into other organs for they function as the transport channels of metastatic cells, implying that neovascularization is necessary in metastasis. The dependency of tumor progression on angiogenesis,\(^3\) together with its vital
function in the pathological development and metamorphosis of neoplastic cells, makes this cascade an attractive target in cancer therapy.\(^6\)

Impairment of signal transduction, due to genetic and epigenetic modifications, is a defining characteristic of cancer.\(^7\) Previous accounts have shed light on the significance of molecular interactions and signaling pathways in carcinogenesis.\(^8\) Neovascularization is affected by a number of molecular mediators such as growth factors,\(^9\) transcription factors,\(^10\) signaling pathways,\(^11\) extracellular matrix molecules,\(^12\) cytokines,\(^11\) and many others. Due to the undesirable effects that manifest when chemotherapeutic agents attack normal cells, the use of targeted cancer therapy has become more appealing.\(^13\) Through the targeted approach, drug molecules specifically act at the pathways and proteins that serve critical roles in cancer and its microenvironment.\(^14\)

Overexpression of numerous angiogenesis-related proteins is typical in many forms of cancer as they are crucial in the growth, spread, and progression of tumors.\(^3,15\) The complexity of the angiogenic system provides many targets for therapeutic intervention.\(^16\) With the current advances in molecular angiogenesis, novel molecular targets that are overexpressed in cancer have been identified.\(^17\) The vascular endothelial growth factor (VEGF/VEGFR2) pathway constitutes a series of signaling mechanisms that control the proliferation, migration, survival, as well as penetrability of vascular endothelial cells.\(^18\) The phosphorylation of VEGFR2 is recognized as a critical trigger in tumor angiogenesis.\(^19\) Transforming growth factor-beta (TGF-β) is vital for the stabilization of new vessels and is responsible for the production of extracellular matrix and the appropriate interaction between endothelial cells and mural cells.\(^20\) Matrix metalloproteinase-2 (MMP-2) is an extracellular remodeling enzyme that aids in the degradation of the basal membrane required for the migration and infiltration of proliferative endothelial cells in the course of angiogenesis.\(^21\) Dihydrofolate reductase (DHFR) is an enzyme that plays a fundamental role in the synthesis of nucleic acid precursors, which are essential for cell proliferation and growth.\(^22\) Fibroblast growth factor receptors (FGFRs) regulate cell proliferation, differentiation, and angiogenesis.\(^23\) Tie2 is vital in vascular network formation, and its receptors act as regulators of angiogenesis and vessel maturation.\(^24,25\) Insulin-like growth factor-1 receptor (IGF-1R) is commonly overexpressed in cancer.\(^26\) Its signaling initiated by ligand binding mediates many crucial cell responses including angiogenesis, invasion, and metastasis of neoplasia.\(^27,28\) The complex and multifactorial nature of tumor angiogenesis, especially in advanced tumors, necessitates the use of therapeutic compounds that act broadly against cancer-specific targets and pathways in order to reduce challenges associated with developing resistance. Therefore, broadly acting natural drugs with very low toxicity have promising roles in preventing tumor angiogenesis.\(^16\)

The majority of the standard chemotherapeutic agents cause systemic toxicity which impairs several healthy organs/tissues.\(^29\) The toxicities of these drugs on the processes of metabolism and excretion could continuously lead to serious injury to the kidneys, liver, and heart that could, later on, cause coagulopathy and peripheral neuronal toxicity.\(^30\) Thus, there is an urgent need for less toxic drugs that can intercept and cure cancer.

Syringin, also known as Eleutheroside B or in its formal name 4-[(1E)-3-Hydroxy-1-propen-1-yl]-2,6-dimethoxyphenyl D-glucopyranoside (Figure 1), is a phenylpropanoid glycoside present in plants such as Eleutherococcus senticosus,\(^31\) Syringa velutina,\(^32\) Tinospora cordifolia,\(^33\) and numerous others. This compound was known to possess cytotoxic, apoptotic, and antitumor functions in an array of human cancer cell lines.\(^34–37\) These studies suggest that syringin is a promising agent for cancer treatment. Nonetheless, the role of syringin in the inhibition of angiogenesis and its underlying mechanism remains unknown.

**Figure 1** The structure of syringin.
Drug discovery and development is a very costly and extensive procedure. Fortunately, computer-aided drug design (CADD) provides efficiency in minimizing the time, labor, and cost of drug research by the use of computational methods that can speed-up the entire process. These methods were instrumental in the discovery of new antineoplastic drugs that are used today. These include Gefitinib, Erlotinib, Sorafenib, Lapatinib, Abiraterone, and Crizotinib, which are all approved medications that are initially discovered using computational methods.

In this work, reverse molecular docking technique was conducted to understand the interaction of syringin with the molecular mediators involved in the multifaceted interplay in angiogenesis. The anti-angiogenic activity of syringin was evaluated through the chorioallantoic membrane (CAM) assay and the probable molecular targets of the title compound were identified using the reverse docking technique. Furthermore, in silico assessment of drug-likeness and the compound’s absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties were also performed to predict the safety and oral drug-likeness of syringin.

Materials and Methods
Reagents and Materials
Syringin (≥98% purity) was acquired from ChemFaces (Wuhan, China), and the standard Celecoxib (≥98% purity) was purchased from Sigma Aldrich (St. Louis, MO, USA). Phosphate buffer saline (PBS) was bought from Gibco (Waltham, MA, USA), while dimethylsulfoxide (DMSO) was obtained from J.T. Baker (Center Valley, PA, USA). All the other chemicals and reagents used in this study were of analytical reagent grade. Additionally, fertilized duck eggs were purchased from a hatchery in Balian, Bulacan, Philippines.

Chick Chorioallantoic Membrane (CAM) Assay
The effect of syringin on angiogenesis was evaluated through chorioallantoic membrane (CAM) assay as per the protocol of Thanekar et al. with minor modifications on the method of analyzing vascular branching and choice of positive control. A total of six fertilized duck eggs were tested per group and were incubated using an Incubox automatic turning incubator maintained at 37°C with 85% relative humidity. Eggs between the 8th and 10th day of embryonic development (the peak of CAM neovascularization) were utilized. Prior to the assay, the access portal was prepared by locating the embryo using a light source. Thereafter, the eggshells were marked and sanitized using 70% alcohol to create a 1-cm² window. The entire experiment was performed under sterile conditions to avoid contaminants. The incubator was disinfected and the tools were autoclaved before use.

Celecoxib (200 μM) and syringin at various concentrations (12.5 μM, 25 μM, 50 μM, 100 μM, 200 μM) were dissolved in dimethylsulfoxide (DMSO, 0.1% v/v) with phosphate buffer saline (PBS). At day 8 of embryonic development, sterile filter paper discs (10 mm) loaded with 100 μL of syringin, celecoxib, and 0.1% DMSO were aseptically placed over the blood vessel of a growing CAM through the access portal. Later on, adhesive tape was used to seal the eggshell, and the eggs were returned to the humidified incubator. After 48 hours, the eggs were reopened and the CAMs were observed and photographed. Photographs of the chorioallantoic membranes (CAMs) with the highest quality were chosen. The chosen visual field represents the region around the filter paper disc with the tested compounds. Photographs were taken at the same distance from the egg window to the lens of the camera. Through Angioquant version 1.33 (MATLAB Inc., Tampere, Finland), a software program for the analysis of blood vessels in images, the digital figures of the CAMs were inspected and parameters such as vessel length and its junctions were quantified. The anti-angiogenic effect was then calculated using the following formula:

\[
\text{Percentage inhibition} = \frac{\text{score of control vessels} - \text{score of treated vessels}}{\text{score of control vessels}} \times 100
\]

Molecular Modeling
Computational Tools
Protein-Ligand docking was accomplished with the use of Autodock Vina 1.1.2 in Python Prescription (PyRx) software, installed in an iMac desktop computer, equipped with 3.1 GHz Intel Core i7 processor, 16GB RAM, and an NVIDIA GeForce 750M graphics card. Autodock Vina utilizes AMBER force field as the scoring parameter for molecular docking.

Preparation of 3D Structure of Ligands and Protein Targets
The crystal structures of dihydrofolate reductase (PDB ID: 1DRE), transforming growth factor-beta receptor type 1
(PDB ID: 1VJY), vascular endothelial growth factor receptor 2 (PDB ID: 3EWH), matrix metalloproteinase-2 (PDB ID: 1HOV), and other angiogenesis-related proteins were downloaded from Research Collaboratory for Structural Bioinformatics ( RCSB) Protein Data Bank. Protein preparation was carried out using the UCSF Chimera 1.13 software and AutoDock tools of PyRx. Co-crystallized ligands, solvents, water molecules, and ions were removed, except for the ions that present essential roles in the ligand–target interaction. The location of the reference ligand in the protein structure was recorded and used to serve as the target site. Afterwards, the co-crystallized ligand was deleted to allow the interaction of test compounds with the binding site. The three-dimensional (3D) structure of ligands such as syringin (CID 5316860) (https://pubchem.ncbi.nlm.nih.gov/compound/Syringin), as well as the other inhibitors evaluated, were retrieved from the PubChem compound database. The ligands were minimized in the OpenBabel tool using Universal Force Field (UFF) and then converted into AutoDock ligand format (PDBQT), which is suitable for docking in PyRx.

Reverse Molecular Docking

The potential targets of syringin in the cascade of angiogenesis were virtually examined by reverse docking approach to determine the probable targets of this ligand. Commonly known molecular targets involved in angiogenesis were chosen, and the binding modes, binding affinity, as well as the residue interaction of syringin on the active site of these proteins were determined. A grid-based docking method using a rigid protein receptor and flexible ligand was utilized in the experiment. The grid box was optimized to attain the best binding pose of the redocked native ligand which exhibits high similarity to the original co-crystallized ligand. The residues featured in the docking interaction, RMSD value, and generated pose were the basis in validating the docking parameters. The grid optimization protocol was executed using Autodock Vina, and the grid box encompasses the area containing the amino acid residues of the target binding site.

Listed in Table 1 are the important residues enclosed in the grid box as well as the grid box parameters of selected target proteins. The featured residues, RMSD value, and pose were the basis in evaluating the validity of the docking procedure. The structures of the crystallized and redocked ligands were inspected using UCSF chimera 1.13 software (San Francisco, CA, USA). The two structures were superimposed and each pair of atoms was manually selected to calculate the root main square deviation (RMSD) values of the overlapped structures. The RMSD is a measure of the accuracy of the docking protocol used, an RMSD value of <2 Å being deemed successful. Moreover, the docking poses and ligand interactions were viewed using Biovia Discovery Studio Visualizer 2019 (Accelrys Inc., San Diego, CA, USA) to visually confirm if the essential residues and interactions observed in the crystal structure were maintained in the simulated structure.

ADMET and Toxicity Predictions

Aside from having therapeutic efficacy, it is also of prime importance that drug candidates possess excellent ADMET

<table>
<thead>
<tr>
<th>PDB ID</th>
<th>Protein Target</th>
<th>Essential Residues Enclosed in the Grid Box</th>
<th>Coordinates of the Center</th>
<th>Dimension of the Grid Box</th>
</tr>
</thead>
<tbody>
<tr>
<td>3EWH</td>
<td>Vascular endothelial growth factor receptor 2 (VEGFR2)</td>
<td>Leu840, Val848, Ala866, Lys868, Glu885, Leu889, Ile892, Val898, Thr916, Glu917, Cys919, Leu1019, His1026, Leu1035, Cys1045, Asp1046, and Phe1047</td>
<td>x=17.001, y=−5.309, z=11.075</td>
<td>x=18.962 Å, y=19.437 Å, z=23.602 Å</td>
</tr>
<tr>
<td>1VJY</td>
<td>Human transforming growth factor-beta receptor type 1 (TGF-β1)</td>
<td>Ile211, Val219, Ala230, Lys232, Tyr249, Leu260, Phe262, Leu278, Ser280, Tyr282, His283, Leu340, Ala350, Asp351</td>
<td>x=15.853, y=70.735, z=4.389</td>
<td>x=32.689 Å, y=28.794 Å, z=21.028 Å</td>
</tr>
<tr>
<td>1HOV</td>
<td>Matrix metalloproteinase-2 (MMP-2)</td>
<td>Leu42, Leu82, Leu83, Ala84, His85, Phe115, Leu116, Val117, His120, Glu121, His130, Leu137, Ile141, Thr143, Phe148, and Zinc166</td>
<td>x=6.559, y=15.950, z=19.597</td>
<td>x=22.177 Å, y=23.460 Å, z=20.555 Å</td>
</tr>
<tr>
<td>1DRE</td>
<td>Dihydrofolate reductase (DHFR)</td>
<td>Ile5, Ala6, Ala7, Met20, Asp27, Lys32, Ser49, Ile50, Arg52, Arg57, Ile94, Tyr100</td>
<td>x=18.429, y=18.855, z=35.237</td>
<td>x=23.897 Å, y=23.201 Å, z=20.492 Å</td>
</tr>
</tbody>
</table>
(Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. In this study, syringin was analyzed using the ADMET and TOPKAT (Toxicity Prediction by Computer Assisted Technology) modules of Biovia Discovery Studio 2.5 (Accelrys Inc., San Diego, CA, USA). The ADMET descriptors protocol includes the determination of human intestinal absorption, aqueous solubility, blood-brain barrier (BBB) penetration, plasma protein binding, CYP2D6 inhibition, and hepatotoxicity. A quantitative structure–activity relationship (QSAR) model was utilized by this module to examine various attributes of the test compound. Meanwhile, carcinogenicity, mutagenicity, skin irritant activity, and others were evaluated using the TOPKAT module. The toxicity prediction protocol performs the assessment on a series of toxicity endpoints frequently employed in drug development. Furthermore, the conformance of syringin to Lipinski’s rule of five was also assessed.

**Statistical Analysis**

Analysis of data was conducted using one-way analysis of variance (ANOVA), together with post hoc Tukey’s comparison test in GraphPad Prism version 6.01 (San Diego, CA, USA). Values were presented as mean ± SD, and findings were regarded as statistically significant when $P < 0.05$.

**Results and Discussion**

**Anti-Angiogenic Activity**

Assessment of the anti-angiogenic responses of the drug was accomplished using the chorioallantoic membrane (CAM) assay. This assay is considered as the most widely used method in the evaluation of agents that affect blood vessel formation. DMSO at 0.1% concentration was used as the vehicle of the compounds and served as the negative control. Celecoxib was used as the positive control due to its established inhibitory activity in angiogenesis.

The results of the chorioallantoic membrane (CAM) assay are summarized in Table 2. Celecoxib at 200 µM inhibited the total number of junctions by 62.08 ± 5.60% ($P < 0.0001$). Meanwhile, at 12.5 µM, 25 µM, 50 µM, 100 µM, and 200 µM concentrations, syringin was able to decrease the total number of junctions by 22.83 ± 2.3%, 29.81 ± 3.4%, 39.61 ± 3.3%, 63.19 ± 2.34%, and 66.98 ± 3.62%, respectively. When it comes to vessel length, celecoxib at 200 µM was able to shorten it by 45.83±9.94% ($P < 0.0001$), whereas syringin at 12.5 µM, 25 µM, 50 µM, 100 µM, and 200 µM reduced vessel length by 10.38 ± 4.16%, 14.64 ± 3.15%, 25.42 ± 6.74%, 44.15 ± 8.20%, and 55.14 ± 8.94%, respectively. It is also noteworthy that at 100 µM and 200 µM, the activity of syringin is comparable with the percentage inhibition of 200 µM celecoxib. These results demonstrate that syringin exhibits a significant dose-dependent decrease in the total number of junctions from 12.5 µM to 200 µM, and mean vessel length from 50 µM to 200 µM in comparison with the negative control group ($P < 0.0001$). Representative images of treated membranes (Figure 2), and the percentage inhibition of the total number of junctions and mean length of blood vessels, as functions of concentration, are illustrated in Figure 3A and B, respectively.

**Reverse Molecular Docking Analysis**

It has been established that molecular docking is considered as a top screening approach in drug discovery and development. We demonstrated the utility of this technique in discovering new inhibitors of various druggable targets in *M. tuberculosis*. Reverse or inverse molecular docking helps in determining the probable protein targets of a ligand and shed some light on the possible mechanism of action of a drug. In this study, reverse docking was conducted to investigate the interaction between syringin and various angiogenesis-related proteins at the molecular level, particularly examining the hydrogen bonds, van der Waals and hydrophilic interactions, which

<table>
<thead>
<tr>
<th>Treatment Groups</th>
<th>Percentage Inhibition of Total Number of Junctions</th>
<th>Percentage Inhibition of Mean Length of Blood Vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syringin 200 µM</td>
<td>66.98 ± 3.62*</td>
<td>55.14 ± 8.94*</td>
</tr>
<tr>
<td>Syringin 100 µM</td>
<td>63.19 ± 2.34*</td>
<td>44.15 ± 8.20*</td>
</tr>
<tr>
<td>Syringin 50 µM</td>
<td>39.61 ± 3.3*</td>
<td>25.42 ± 6.74*</td>
</tr>
<tr>
<td>Syringin 25 µM</td>
<td>29.81 ± 3.4*</td>
<td>14.64 ± 3.15*</td>
</tr>
<tr>
<td>Syringin 12.5 µM</td>
<td>22.83 ± 2.34*</td>
<td>10.38 ± 4.16*</td>
</tr>
<tr>
<td>Celecoxib 200 µM (Positive control)</td>
<td>62.08 ± 5.60*</td>
<td>45.83 ± 9.94*</td>
</tr>
<tr>
<td>0.1% DMSO (Negative control)</td>
<td>-0.01 ± 1.92</td>
<td>0 ± 5.46</td>
</tr>
</tbody>
</table>

Notes: Values are summarized as mean ± standard deviation, (n = 6). * P value < 0.0001 vs 0.1% DMSO (negative control group). † P value < 0.05 vs 0.1% DMSO (negative control group).
are the principal driving force in maintaining a stable ligand-protein complex.77

Syringin–DHFR Interaction

The folate pathway has been regarded as a crucial target in cancer chemotherapy. Dihydrofolate reductase (DHFR) is an enzyme that plays a fundamental role in the synthesis of nucleic acid precursors and is essential for cell proliferation and growth.22 It catalyzes the reduction of dihydrofolate to tetrahydrofolate through NADPH, a pocket situated deep within the enzyme.78 Meanwhile, methotrexate is an anti-folate agent available in the market for various types of cancer.79 However, aside from its poor pharmacokinetic property, its side effects include myelosuppression as well
as impairment of the gastrointestinal tract, kidneys, and liver. Unfortunately, there is no available structure of DHFR from a human organism that is in complex with methotrexate, a standard antifolate drug. In contrast, ample literature shows that DHFR (eg, 1DRE) with methotrexate is common in the E. coli organization. A recent paper by Hobani et al also used the 1DRE structure to compare the effect of curcumin to methotrexate at the active site of DHFR protein. Thus, the interaction of syringin with DHFR using the 1DRE crystal structure was investigated. The RMSD value of the redocked ligand was 0.844 Å, which is within the accepted range. Syringin formed a complex with DHFR through six conventional hydrogen bonds with Ala6, Asn18, Ala19, Ser49, and Thr113. The other residues that had an interaction with the ligand include Ala7, Ile14, Met20, Phe31, and Tyr100. Syringin had a binding affinity of −9.0 kcal/mol, whereas the redocked methotrexate ligand had −8.0 kcal/mol. These results indicate that the binding of syringin with DHFR is stronger than the known ligand, methotrexate. Figure 4A shows the docked structures of syringin together with the antifolate drug methotrexate on the active site of 1DRE, Figure 4B shows the 3D image of syringin on the hydrogen bond surface of the protein, while Figure 4C and D demonstrate the 2D interaction diagrams of methotrexate and syringin with 1DRE, respectively.

**Syringin–TGF-βR1 Interaction**

The transforming growth factor-β (TGF-β) pathway has been recognized as a mediator of numerous cellular responses affecting cancer. In the case of human transforming growth factor-beta receptor type 1 (PDB ID: 1VJY),

![Figure 4](image-url)

*Figure 4 (A) Binding mode of syringin (yellow sticks) and methotrexate (green sticks) on the active site of dihydrofolate reductase (DHFR); (B) 3D docking snapshot with syringin on the surface of DHFR; (C) 2D interaction diagram of the native ligand (methotrexate) with DHFR; (D) 2D interaction diagram of syringin with DHFR.*
the key residues of this protein are Lys232, Leu260, Ser280, His283, and Asp351. As shown in Figure 5D, syringin had an interaction with all of the key residues, such as conventional hydrogen bond with Asp351 (Figure 5B), pi-cation with Lys232, pi-alkyl with Leu260, and van der Waals interaction with Ser280 and His283. Ser280 is considered a critical residue required for inhibitor selectivity, to which syringin had a van der Waals interaction. Compound 460 (Figure 5C), the redocked reference ligand, had a binding energy of −10.2 kcal/mol, while syringin had −8.7 kcal/mol. LY-580276 (Figure 5E), an established inhibitor, had a binding energy of −9.6 kcal/mol. The superimposed 3D interaction diagrams of syringin, compound 460, and LY-580276 at the active site of 1VYJ are presented in Figure 5A. Although considered comparable, the binding affinity of syringin with TGF-βR1 protein target is slightly inferior compared to compound 460 and LY-580276.

**Syringin–VEGFR2 Interaction**

The VEGF/VEGFR2 pathway constitutes a series of signaling mechanisms that controls the proliferation, migration, survival, as well as penetrability of vascular endothelial cells. For the VEGFR2 kinase domain (PDB ID: 3EWH), Glu885, Cys919, and Asp1046 are recognized as the key residues to which a compound will bind to for optimal interaction with the protein. Cys919 acts as a predominant residue responsible for the maintenance of inhibitor activity. As shown in Figure 6B and D, syringin had a conventional hydrogen bond with Cys919 similar to the co-crystallized ligand, k11 (Figure 6C); while vandetanib (Figure 6E), an established inhibitor of VEGFR2, had an unfavorable interaction with the said residue. Furthermore, syringin formed van der Waals interaction with Glu885 and conventional hydrogen bond with Asp1046; vandetanib had a van der Waals interaction with both Glu885 and Asp1046; whereas k11 had an unfavorable interaction with Glu885 and Asp1046. The binding energy of syringin was −7.5 kcal/mol, while that of vandetanib and k11 were −8.8 kcal/mol and −12.2 kcal/mol, respectively. Figure 6A depicts the binding mode of syringin along with vandetanib and the native ligand at the active site of 3EWH. Despite the excellent binding affinity of k11, it has...
a molecular weight of 527.511 g/mol,\textsuperscript{85} which makes it quite undesirable as an oral drug candidate according to the Lipinski’s rule.\textsuperscript{60}

Syringin–MMP-2 Interaction
Matrix metalloproteinase-2 (MMP-2) is capable of degrading elastin, fibronectin, gelatin, as well as collagen types IV, V, VI, and X,\textsuperscript{86} which are all recognized as part of the principal components of the extracellular matrix.\textsuperscript{87} Numerous accounts supported the claim that a decrease in MMP-2 expression resulted in significant inhibition of angiogenesis in cancer.\textsuperscript{88–91} According to Agrawal et al, binding with zinc is usually regarded as a requirement for MMP inhibitors.\textsuperscript{92} Figure 7D shows that when syringin was docked against MMP-2 (PDB ID: 1HOV), it exhibited pi–cation interaction with Zinc166. It also had a conventional hydrogen bond with Ala84 (Figure 7B and D), an extremely conserved residue in the target site of MMP. Moreover, His120 and His130 are some of the residues also present at the active site of the protein, and the compound of interest demonstrated pi–pi stacked and van der Waals interaction with those residues, respectively. Van der Waals interaction was also formed with Leu83, another backbone residue of 1HOV.\textsuperscript{93,94}

The other interactions of syringin include conventional hydrogen bond with His85 and Ala139, carbon hydrogen bond with Glu121, and van der Waals interaction with Ile141 and Tyr142. The native ligand (i52) had a pi–cation interaction with Zinc166, conventional hydrogen bond with Ala84, pi–pi stacked interaction with His120, and carbon hydrogen bond with His130 (Figure 7C). Meanwhile, the known inhibitor marimastat (Figure 7E) had the following interactions with the crucial amino acid residues at the active site: conventional hydrogen bond with Ala84, carbon hydrogen bond with His120 and His130, and van der Waals interaction with Zinc166. Syringin, marimastat, and i52 were observed to bind into the active site of the protein cavity with a good fit (Figure 7A). Syringin exhibited a binding energy of −6.9 kcal/mol, while marimastat and i52 had −6.6 kcal/mol and −8.0 kcal/mol, respectively.
Although iS2 exhibited better binding affinity than syringin, iS2 and marimastat both contain a hydroxamic acid moiety, which is linked to toxicity as well as mutagenicity, and has been documented to manifest unfavorable pharmacokinetics. In this work, the ADMET and TOPKAT calculations (vide infra) indicate that syringin would most likely be nontoxic especially to the liver. Due to the unwanted effects exhibited by known inhibitors of MMP-2, new and effective MMP-2 suppressive agents with a safer profile must be explored.

As summarized in Table 3, syringin potentially binds to numerous angiogenesis-related proteins such as DHFR, TGF-βR1, VEGFR2, and MMP-2. Although its binding affinity with these proteins may not be as high as some of the co-crystallized ligands and known inhibitors, syringin virtually binds with a multitude of proteins involved in neovascularization indicating the possible mechanism behind its anti-angiogenic activity.

**ADMET Profile**

The utmost reasons for the failure of the majority of drug candidates in clinical trials are inadequate ADME (absorption, distribution, metabolism, excretion) and high toxicity. Therefore, early assessment of the pharmacokinetics and toxicity profiles is vital in drug discovery. Syringin was reported to possess hepatoprotective and cardioprotective properties, which are desirable properties of an anti-cancer/anti-angiogenic agent. The majority of the standard chemotherapeutic medications cause systemic toxicity, which leads to serious injury to the liver and heart. Hence, prevention of these toxicities is vital for cancer survival. Thus, ADMET predictions were performed on syringin. Table 4 indicates that syringin would exhibit outstanding qualities as a drug candidate. Since the brain is not the target location in this study, it is desirable that the experimental compound does not penetrate the blood-brain barrier (BBB) to diminish any possible disturbances to the brain homeostasis. Delightfully,
Table 3 Root-Mean-Square Deviation (RMSD) Values and Binding Energies for Syringin and Native Ligands in Complex with Various Angiogenesis Proteins

<table>
<thead>
<tr>
<th>PDB ID</th>
<th>Protein Target</th>
<th>RMSD</th>
<th>Native Ligand Binding Energy (kcal/mol)</th>
<th>Syringin Binding Energy (kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1DRE</td>
<td>Dihydrofolate reductase (DHFR)</td>
<td>0.844</td>
<td>-8.0</td>
<td>-9.0</td>
</tr>
<tr>
<td>1VY</td>
<td>Transforming growth factor-beta receptor type 1 (TGF-βR1)</td>
<td>0.551</td>
<td>-10.2</td>
<td>-8.7</td>
</tr>
<tr>
<td>3EWH</td>
<td>Vascular endothelial growth factor receptor 2 (VEGFR2)</td>
<td>0.706</td>
<td>-12.2</td>
<td>-7.5</td>
</tr>
<tr>
<td>1HOV</td>
<td>Matrix metalloproteinase 2 (MMP-2)</td>
<td>1.135</td>
<td>-8.0</td>
<td>-6.9</td>
</tr>
<tr>
<td>4QQ5</td>
<td>Fibroblast growth factor receptor 4 (FGR4)</td>
<td>1.345</td>
<td>-10.9</td>
<td>-7.9</td>
</tr>
<tr>
<td>1T46</td>
<td>c-Kit</td>
<td>0.104</td>
<td>-12</td>
<td>-7.8</td>
</tr>
<tr>
<td>3POZ</td>
<td>Epidermal growth factor receptor (EGFR)</td>
<td>1.144</td>
<td>-10.6</td>
<td>-7.6</td>
</tr>
<tr>
<td>4FA2</td>
<td>P38 mitogen-activated protein kinase (MAPK)</td>
<td>0.520</td>
<td>-9.9</td>
<td>-7.3</td>
</tr>
<tr>
<td>2OJ9</td>
<td>Insulin-like growth factor-1 receptor (IGF-1R)</td>
<td>1.043</td>
<td>-9.8</td>
<td>-7.2</td>
</tr>
<tr>
<td>1UV5</td>
<td>Glycogen Synthase Kinase 3B</td>
<td>0.554</td>
<td>-10</td>
<td>-7.2</td>
</tr>
<tr>
<td>3HNG</td>
<td>Vascular endothelial growth factor receptor 1 (VEGFR1)</td>
<td>0.511</td>
<td>-10.6</td>
<td>-7.1</td>
</tr>
<tr>
<td>2P4I</td>
<td>Tie-2</td>
<td>1.353</td>
<td>-12.0</td>
<td>-7.1</td>
</tr>
<tr>
<td>2X9F</td>
<td>EphB4</td>
<td>0.925</td>
<td>-8.0</td>
<td>-7.0</td>
</tr>
<tr>
<td>5EW8</td>
<td>Fibroblast growth factor receptor 1 (FGFR1)</td>
<td>1.136</td>
<td>-8.3</td>
<td>-6.9</td>
</tr>
<tr>
<td>3C1O</td>
<td>Histone deacetylase 7 (HDAC7)</td>
<td>0.991</td>
<td>-7.8</td>
<td>-6.8</td>
</tr>
<tr>
<td>4XUF</td>
<td>FMS-like tyrosine kinase-3 (FLT3)</td>
<td>1.462</td>
<td>-11.3</td>
<td>-6.4</td>
</tr>
<tr>
<td>4WUA</td>
<td>Serine-arginine protein kinase 1 (SRPK1)</td>
<td>0.951</td>
<td>-9.1</td>
<td>-6.2</td>
</tr>
<tr>
<td>3ERT</td>
<td>ER-α</td>
<td>1.076</td>
<td>-8.5</td>
<td>-5.8</td>
</tr>
<tr>
<td>3CF4</td>
<td>Fibroblast growth factor receptor (FGFR)</td>
<td>0.572</td>
<td>-9.8</td>
<td>-5.5</td>
</tr>
<tr>
<td>1UWJ</td>
<td>B-RAF</td>
<td>1.018</td>
<td>-12.3</td>
<td>-8.1</td>
</tr>
<tr>
<td>3PP0</td>
<td>Human epidermal growth factor receptor 2 (HER2)</td>
<td>0.679</td>
<td>-11.2</td>
<td>-8.1</td>
</tr>
<tr>
<td>2DQM</td>
<td>Aminopeptidase N</td>
<td>0.966</td>
<td>-8.8</td>
<td>-7.7</td>
</tr>
<tr>
<td>5JFR</td>
<td>Methionine amino peptidase 2 (MetAp2)</td>
<td>0.325</td>
<td>-8.6</td>
<td>-7.3</td>
</tr>
</tbody>
</table>

The ADMET results show that syringin has a very low permeation ability to the BBB. Furthermore, the title compound exhibits optimal solubility, a vital characteristic that affects the bioavailability of the drug. On the other hand, the absorption level of syringin was shown to be moderate, a characteristic that can be easily addressed by formulating the compound into a dosage form suitable for drugs with moderate absorption. Syringin was also predicted to be nontoxic to the liver, not bound to plasma proteins, and is not an inhibitor of CYP 2D6, suggesting that it will not cause drug-induced hepatotoxicity, is highly efficient in traversing cell membranes, therefore greater possibility to get to the target site, and less likely to affect the plasma concentration of other medications. These information indicate that there is a low probability that syringin will elicit drug–drug interactions at the pharmacokinetic level.

Furthermore, the TOPKAT data (Table 5) show that syringin is a non-carcinogenic, non-mutagenic, and non-skin irritant agent. Additionally, Table 6 indicates that the computed lethal dose 50 (LD50) of syringin in rats is 10,000 mg/kg, which, according to Hodge and Sterner toxicity scale, is classified as practically non-toxic. Notably, the predicted maximum tolerated dose of the compound in rat models is 861 mg/kg. These findings matched the in vivo study of Krishnan et al who conducted a toxicity investigation of syringin. Signs and symptoms of toxicity such as agitation, pulmonary distress, diarrhea, convulsions, and coma did not occur on Wistar rats administered with 10, 20, 30, 50, and
Table 5 Toxicity Profile of Syringin

<table>
<thead>
<tr>
<th>TOPKAT Descriptors</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight of Evidence (WOE) Probability of Carcinogenicity</td>
<td>Non-carcinogen</td>
</tr>
<tr>
<td>Aerobic Biodegradability</td>
<td>Biodegradable</td>
</tr>
<tr>
<td>AMES Mutagenicity</td>
<td>Non-Mutagen</td>
</tr>
<tr>
<td>AMES Single Benz</td>
<td>Non-mutagen</td>
</tr>
<tr>
<td>Skin irritation</td>
<td>Non-skin irritant</td>
</tr>
</tbody>
</table>

Table 6 Toxicity Prediction of Syringin in Rat Models

<table>
<thead>
<tr>
<th>MODEL: Rat Oral LDS50 (v3.1)</th>
<th>Computed Rat Oral LDS50 Log (1/Moles) = 0.804</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computed Rat Oral LDS50</td>
<td>10 g/kg</td>
</tr>
<tr>
<td>Lower 95% Confidence Limits</td>
<td>10 g/kg</td>
</tr>
<tr>
<td>Upper 95% Confidence Limits</td>
<td>10 g/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MODEL: Rat Maximum Tolerated Dose – Feed/Water (v6.1)</th>
<th>Computed Log (1/mol) = 2.636</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computed Maximum Tolerated Dose</td>
<td>861.0 mg/kg</td>
</tr>
<tr>
<td>Lower 95% Confidence Limits</td>
<td>99.7 mg/kg</td>
</tr>
<tr>
<td>Upper 95% Confidence Limits</td>
<td>7.4 mg/kg</td>
</tr>
</tbody>
</table>

Table 7 Drug-Like Properties of Syringin

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result</th>
<th>Acceptable Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octanol/Water Partition Coefficient (LogP)</td>
<td>2.083250</td>
<td>≤5</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>372.37 g/mol</td>
<td>≤500</td>
</tr>
<tr>
<td>Hydrogen Bond Acceptor</td>
<td>9</td>
<td>≤10</td>
</tr>
<tr>
<td>Hydrogen Bond Donor</td>
<td>5</td>
<td>≤5</td>
</tr>
<tr>
<td>Topological Polar Surface Area</td>
<td>138</td>
<td>&lt;140Å²</td>
</tr>
</tbody>
</table>

100 mg/kg body weight of the test compound. These results imply that syringin is safe to use in in vivo analyses and possesses features worthy of further development into a clinically applicable drug.

The drug-like properties of syringin were also evaluated based on the Lipinski’s rule of five. According to this rule, compounds with a partition coefficient (LogP) ≤5, molecular weight ≤500, quantity of hydrogen bond acceptors ≤10, quantity of hydrogen bond donors ≤5, and topological polar surface area (TPSA) <140Å² are likely to exhibit good oral bioavailability, smooth membrane permeability as well as favorable gastrointestinal absorption. Table 7 reveals that syringin perfectly complies with the criteria of the Lipinski’s rule, suggesting that this compound can be further developed as an oral drug for cancer. Furthermore, since it is predicted that the drug has a high maximum tolerated dose index, moderate to high doses may be considered to attain optimal inhibition of neovascularization.

Conclusion

The ever increasing incidence of cancer is making it a very serious health concern worldwide and attracts great interest in the field of medicinal research. For many years, plants, herbs, and other natural products have been utilized as therapeutic agents. Syringin, a phenylpropanoid compound present in diverse plant families, has been reported to elicit cytotoxicity and apoptotic activity. In this work, the chorioallantoic membrane (CAM) assay was conducted to assess the effect of the test compound on neovascularization. The results showed that the anti-angiogenic activity of syringin at 100 µM and 200 µM is comparable with 200 µM of celecoxib, the positive control. Furthermore, the reverse molecular docking study unveiled the probable angiogenesis targets that were inhibited by syringin as manifested in the CAM assay. Specifically, the activity of syringin was likely mediated by the inhibition of dihydrofolate reductase (DHFR), transforming growth factor-beta receptor type 1 (TGF-βR1), vascular endothelial growth factor receptor 2 (VEGFR2), and matrix metalloproteinase-2 (MMP-2). These results will guide future enzyme-based assays that will further validate the anti-angiogenic action of syringin. In fact, further in vitro investigations are underway in our group. It is also noteworthy that syringin is a good candidate for drug development as it exhibited outstanding ADMET and drug-like properties. This is the first study to substantiate the angiogenesis inhibitory action of syringin and its probable mechanism of action, demonstrating that it may be a feasible multi-targeted agent for anti-angiogenic cancer therapy.

Acknowledgments

This study was funded by the Institutional Grant for Invigorating Basic Research on Health Sciences Phase II research program of the Department of Science and Technology-National Research Council of the Philippines (Project No. Q-006). The authors are also thankful to The Graduate School and the Research Center for the Natural
and Applied Sciences, University of Santo Tomas, Manila, Philippines, as well as to the staff of the Emerging Interdisciplinary Research (EIDR) laboratory (OVPAA-EIDR 12-001-121102) of the University of the Philippines Manila for the training, assistance, and for allowing them to use the facilities.

Disclosure
The authors report grants from the National Research Council of the Philippines during the conduct of the study. The authors report no other potential conflicts of interest in this work.

References


Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/drug-design-development-and-therapy-journal